Jay Moorin, Partner
Moorin has been a managing member of the General Partner
and of ProQuest since its founding in 1998. He is a seasoned
healthcare executive whose background includes senior roles
in leading investment banking, pharmaceutical and biotech
companies. Mr. Moorin led ProQuest's investments in U.S.
Bioscience, Epic Therapeutics, and Pharmion, among others.
He currently serves on the Board of Directors of ACMI, Acurian, Gloucester Pharmaceuticals, Guava Technologies, and Novacea.
to joining ProQuest, Mr. Moorin served as Chairman, President
and Chief Executive Officer of Magainin Pharmaceuticals,
Inc. (now Genaera Corp.), a venture-backed biotechnology
company developing novel antibiotics and oncology drugs.
During his tenure at Magainin, Mr. Moorin raised over $150
million in private and public capital, oversaw the development
of a new technology from initial discovery through clinical
research to a New Drug Application with the FDA, and forged
collaborations with leading pharmaceutical companies such
as SmithKline Beecham and Sandoz (now Novartis). Previously,
as Managing Director, Health Care Banking at Bear, Stearns & Co.,
Inc., he was involved in a number of innovative transactions,
including managing one of the first biotech mergers, privatizing
a specialty pharmaceutical firm, and closing one of the first
PIPE financings for a biotech company. In 1983, he joined
E.R. Squibb and Sons Pharmaceuticals, Inc., where he held
positions in marketing, strategy and general management,
ultimately becoming the youngest vice president in the corporation
at that time, serving as Vice President of Marketing & Business
Development in the SquibbMark Division.
Mr. Moorin was appointed to the position of Adjunct Senior
Fellow of the Leonard Davis Institute of Health Economics at
the University of Pennsylvania. He holds a B.A. with distinction
in economics from the University of Michigan.